Harel Dahari, PhD | Loyola Medicine

Harel Dahari, PhD

Harel Dahari, PhD


Associate Professor

Languages Spoken

English, Hebrew

Clinical Expertise



Medical Education

Medical School

Board Certification


  • Accounting for Space—Quantification of Cell-To-Cell Transmission Kinetics Using Virus Dynamics Models. Kumberger, P; Durso-Cain, K; Uprichard, SL; Dahari, H; Graw, F, Viruses
  • Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics Ishida, Y.; Chung, T. L.; Imamura, M.; Hiraga, N.; Sen, S.; Yokomichi, H.; Tateno, C.; Canini, L.; Perelson, A. S.; Uprichard, S. L.; Dahari, H.; Chayama, K., Hepatology (Baltimore, Md.)
  • High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members Boodram, B.; Hotton, A. L.; Shekhtman, L.; Gutfraind, A.; Dahari, H., Journal of urban health : bulletin of the New York Academy of Medicine
View All ResearchShow Less
  • How to eliminate HCV in people who inject drugs in the USA Dahari, H.; Boodram, B., The Lancet.Infectious diseases
  • Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users. Major, M; Gutfraind, A; Shekhtman, L; Cui, Q; Kachko, A; Cotler, SJ; Hajarizadeh, B; Sacks-Davis, R; Page, K; Boodram, B; Dahari, H, Science translational medicine
  • Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics Reinharz, V.; Dahari, H.; Barash, D., Mathematical biosciences
  • End of treatment RNA-positive/sustained viral response in an individual with acute hepatitis C virus infection treated with direct-acting antivirals Shteyer, E.; Dahari, H.; Gafanovich, I.; Dery, I.; Wolf, D.; Cotler, S. J.; Lurie, Y., Therapeutic advances in gastroenterology
  • HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients Canini, L.; Imamura, M.; Kawakami, Y.; Uprichard, S. L.; Cotler, S. J.; Dahari, H.; Chayama, K., PLoS ONE
  • Modeling HCV cure after an ultra-short duration of therapy with direct acting agents Goyal, A.; Lurie, Y.; Meissner, E. G.; Major, M.; Sansone, N.; Uprichard, S. L.; Cotler, S. J.; Dahari, H., Antiviral Research
  • Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection Canini, L.; Koh, C.; Cotler, S. J.; Uprichard, S. L.; Winters, M. A.; Han, M. A. T.; Kleiner, D. E.; Idilman, R.; Yurdaydin, C.; Glenn, J. S.; Heller, T.; Dahari, H., Hepatology communications
  • Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies Malespin, M.; Benyashvili, T.; Uprichard, S. L.; Perelson, A. S.; Dahari, H.; Cotler, S. J., Therapeutic advances in gastroenterology
  • Cure prevents more than transmission of HCV Dahari, H.; Cotler, S. J.; Feld, J. J., Hepatology (Baltimore, Md.)
  • HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir simeprevir or ledipasvir, Dahari, H.; Canini, L.; Graw, F.; Uprichard, S. L.; Araujo, E. S.; Penaranda, G.; Coquet, E.; Chiche, L.; Riso, A.; Renou, C.; Bourliere, M.; Cotler, S. J.; Halfon, P., Journal of Hepatology
  • Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report Hasin, Y.; Shteingart, S.; Dahari, H.; Gafanovich, I.; Floru, S.; Braun, M.; Shlomai, A.; Verstandig, A.; Dery, I.; Uprichard, S. L.; Cotler, S. J.; Lurie, Y., WORLD JOURNAL OF HEPATOLOGY
  • Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy DebRoy, S.; Hiraga, N.; Imamura, M.; Hayes, C. N.; Akamatsu, S.; Canini, L.; Perelson, A. S.; Pohl, R. T.; Persiani, S.; Uprichard, S. L.; Tateno, C.; Dahari, H.; Chayama, K., Journal of viral hepatitis
  • Resurrection of response-guided therapy for sofosbuvir combination therapies Dahari, H.; Halfon, P.; Cotler, S. J., Journal of Hepatology
  • Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections Gutfraind, A.; Boodram, B.; Prachand, N.; Hailegiorgis, A.; Dahari, H.; Major, M. E., PLoS ONE
  • Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago Echevarria, D.; Gutfraind, A.; Boodram, B.; Major, M.; Del Valle, S.; Cotler, S. J.; Dahari, H., PLoS ONE
  • Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised double-blind, placebo-controlled phase 2A trial, Koh, C.; Canini, L.; Dahari, H.; Zhao, X.; Uprichard, S. L.; Haynes-Williams, V.; Winters, M. A.; Subramanya, G.; Cooper, S. L.; Pinto, P.; Wolff, E. F.; Bishop, R.; Ai Thanda Han, M.; Cotler, S. J.; Kleiner, D. E.; Keskin, O.; Idilman, R.; Yurdaydin, C.; Glenn, J. S.; Heller, T., The Lancet.Infectious diseases
  • Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach Graw, F.; Martin, D. N.; Perelson, A. S.; Uprichard, S. L.; Dahari, H., Journal of virology
  • Reply: To PMID 25098971. Guedj, J; Canini, L; Cotler, S; Dahari, H, Hepatology (Baltimore, Md.)
  • Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. Canini, L; DebRoy, S; Mariño, Z; Conway, JM; Crespo, G; Navasa, M; D'Amato, M; Ferenci, P; Cotler, SJ; Forns, X; Perelson, AS; Dahari, H, ANTIVIRAL THERAPY
  • Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics Dahari, H.; Shteingart, S.; Gafanovich, I.; Cotler, S. J.; D'Amato, M.; Pohl, R. T.; Weiss, G.; Ashkenazi, Y. J.; Tichler, T.; Goldin, E.; Lurie, Y., Liver international : official journal of the International Association for the Study of the Liver
  • Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C Rotman, Y.; Noureddin, M.; Feld, J. J.; Guedj, J.; Witthaus, M.; Han, H.; Park, Y. J.; Park, S. H.; Heller, T.; Ghany, M. G.; Doo, E.; Koh, C.; Abdalla, A.; Gara, N.; Sarkar, S.; Thomas, E.; Ahlenstiel, G.; Edlich, B.; Titerence, R.; Hogdal, L.; Rehermann, B.; Dahari, H.; Perelson, A. S.; Hoofnagle, J. H.; Liang, T. J., Gut
  • Individualized treatment for patients with low HCV load (genotype 1): a viral kinetic approach Dahari, H.; Cotler, S. J., Hepatology (Baltimore, Md.)
  • Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling. Rong, L; Guedj, J; Dahari, H; Perelson, AS, ANTIVIRAL THERAPY
  • Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling Guedj, J.; Rotman, Y.; Cotler, S. J.; Koh, C.; Schmid, P.; Albrecht, J.; Haynes-Williams, V.; Liang, T. J.; Hoofnagle, J. H.; Heller, T.; Dahari, H., Hepatology (Baltimore, Md.)
  • Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model Rong, L.; Guedj, J.; Dahari, H.; Coffield, D. J., Jr; Levi, M.; Smith, P.; Perelson, A. S., PLoS computational biology
  • Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Guedj, J.; Dahari, H.; Rong, L.; Sansone, N. D.; Nettles, R. E.; Cotler, S. J.; Layden, T. J.; Uprichard, S. L.; Perelson, A. S., Proceedings of the National Academy of Sciences of the United States of America
  • Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection Zhang, J.; Lipton, H. L.; Perelson, A. S.; Dahari, H., Journal of virology
  • Silymarin for HCV infection Polyak, S. J.; Oberlies, N. H.; Pecheur, E. I.; Dahari, H.; Ferenci, P.; Pawlotsky, J. M., ANTIVIRAL THERAPY
  • The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate Guedj, J.; Dahari, H.; Uprichard, S. L.; Perelson, A. S., Expert review of gastroenterology & hepatology
  • Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling Dahari, H.; Cotler, S. J.; Layden, T. J.; Perelson, A. S., Journal of Hepatology
  • The rate of hepatitis C virus infection initiation in vitro is directly related to particle density Sabahi, A.; Marsh, K. A.; Dahari, H.; Corcoran, P.; Lamora, J. M.; Yu, X.; Garry, R. F.; Uprichard, S. L., Virology
  • Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon Dahari, H.; Sainz, B., Jr; Perelson, A. S.; Uprichard, S. L., Journal of virology